Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Current Liabilities (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Total Current Liabilities data on record, last reported at $153.8 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 69.57% year-over-year to $153.8 million; the TTM value through Dec 2025 reached $153.8 million, up 69.57%, while the annual FY2025 figure was $153.8 million, 69.57% up from the prior year.
  • Total Current Liabilities reached $153.8 million in Q4 2025 per TGTX's latest filing, down from $156.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $171.9 million in Q2 2025 and bottomed at $36.4 million in Q3 2022.
  • Average Total Current Liabilities over 5 years is $91.7 million, with a median of $87.6 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: tumbled 58.42% in 2022, then surged 116.92% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $65.4 million in 2021, then dropped by 18.63% to $53.2 million in 2022, then rose by 0.98% to $53.7 million in 2023, then surged by 68.8% to $90.7 million in 2024, then skyrocketed by 69.57% to $153.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $153.8 million in Q4 2025, $156.8 million in Q3 2025, and $171.9 million in Q2 2025.